Icu Medical Inc ICUI
We take great care to ensure that the data presented and summarized in this overview for ICU MEDICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ICUI
View all-
Black Rock Inc. New York, NY3.25MShares$503 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.66MShares$412 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.41MShares$373 Million0.23% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.41MShares$219 Million1.03% of portfolio
-
Wellington Management Group LLP Boston, MA937KShares$145 Million0.03% of portfolio
-
State Street Corp Boston, MA908KShares$140 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY659KShares$102 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il653KShares$101 Million0.02% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN627KShares$97 Million0.03% of portfolio
-
Morgan Stanley New York, NY612KShares$94.7 Million0.01% of portfolio
Latest Institutional Activity in ICUI
Top Purchases
Top Sells
About ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Insider Transactions at ICUI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 06
2024
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Open market or private sale
|
Direct |
2,241
-17.1%
|
$349,596
$156.25 P/Share
|
Dec 02
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-3.51%
|
$1,956,000
$163.14 P/Share
|
Dec 02
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+9.33%
|
$1,056,000
$88.76 P/Share
|
Nov 27
2024
|
David C. Greenberg Director |
SELL
Open market or private sale
|
Direct |
972
-16.18%
|
$153,576
$158.11 P/Share
|
Nov 27
2024
|
David C. Greenberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
972
+13.92%
|
$91,368
$94.68 P/Share
|
Nov 27
2024
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,430
-100.0%
|
$225,940
$158.0 P/Share
|
Nov 27
2024
|
Christian B. Voigtlander Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,430
+50.0%
|
$137,280
$96.83 P/Share
|
Nov 26
2024
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,719
-98.67%
|
$1,227,321
$159.59 P/Share
|
Nov 26
2024
|
Christian B. Voigtlander Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,719
+50.0%
|
$741,024
$96.83 P/Share
|
Nov 25
2024
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,962
-100.0%
|
$331,578
$169.08 P/Share
|
Nov 25
2024
|
Christian B. Voigtlander Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,962
+50.0%
|
$188,352
$96.83 P/Share
|
Nov 01
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-2.67%
|
$2,064,000
$172.26 P/Share
|
Nov 01
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+9.33%
|
$1,056,000
$88.76 P/Share
|
Oct 01
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-2.67%
|
$2,136,000
$178.91 P/Share
|
Oct 01
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+9.33%
|
$1,056,000
$88.76 P/Share
|
Sep 03
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-3.68%
|
$1,956,000
$163.45 P/Share
|
Sep 03
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+3.55%
|
$1,056,000
$88.76 P/Share
|
Aug 30
2024
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Open market or private sale
|
Direct |
2,502
-16.03%
|
$407,826
$163.22 P/Share
|
Aug 16
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-10.29%
|
$1,872,000
$156.04 P/Share
|
Aug 16
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+9.33%
|
$1,056,000
$88.76 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 412K shares |
---|
Open market or private sale | 1.82M shares |
---|---|
Payment of exercise price or tax liability | 185K shares |